ORYZON GENOMICS, S.A. «...678910...» Page 9 out of 13 21/03/2022 07:43 ORYZON GENOMICS, S.A. Other relevant information ORYZON receives approval from the FDA for its IND to conduct FRIDA, a Phase Ib clinical trial with iadademstat in FLT3-mutant relapsed/refractory Acute Myeloid Leukemia patients. Register number: 15080 07/02/2022 11:08 ORYZON GENOMICS, S.A. Annual financial reports and audit reports La sociedad remite el Informe Financiero Anual del ejercicio 2021 Register number: 13925 07/02/2022 09:41 ORYZON GENOMICS, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2021 Register number: 13924 07/02/2022 08:53 ORYZON GENOMICS, S.A. Annual report on directors´ remunerations La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2021 Register number: 13920 07/02/2022 08:26 ORYZON GENOMICS, S.A. Annual corporate governance report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2021 Register number: 13918 04/01/2022 08:00 ORYZON GENOMICS, S.A. Other relevant information ORYZON receives approval to start the Serbian arm of PORTICO, vafidemstat’s Phase IIb trial in Borderline Personality Disorder. Register number: 13462 13/12/2021 08:05 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents new positive efficacy data of iadademstat from the ongoing Phase IIa ALICE clinical trial in acute myeloid leukemia at the ASH-2021 congress. Register number: 13126 12/11/2021 13:28 ORYZON GENOMICS, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 12740 12/11/2021 13:27 ORYZON GENOMICS, S.A. General Shareholders’ Meeting Regulations La sociedad remite el Reglamento de la junta general de accionistas Register number: 12738 28/10/2021 17:44 ORYZON GENOMICS, S.A. Other relevant information La sociedad remite información sobre los resultados del tercer trimestre de 2021 Register number: 12445 Page 9 out of 13 «...678910...»
